Regenix Drugs Profile
Key Indicators
- Authorised Capital ₹ 21.55 Cr
- Paid Up Capital ₹ 18.08 Cr
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.36 Cr
- Satisfied Charges ₹ 17.81 Cr
- Revenue Growth 12.38%
- Profit Growth 246.41%
- Ebitda -8.14%
- Net Worth 20.73%
- Total Assets 15.50%
About Regenix Drugs
Regenix Drugs Limited (RDL) is a leading Public Limited Indian Non-Government Company incorporated in India on 10 May 2007 and has a history of 17 years and nine months. Its registered office is in Chennai, Tamil Nadu, India.
The Corporate was formerly known as Regenix Drugs Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 21.55 Cr and a paid-up capital of Rs 18.08 Cr.
The company currently has active open charges totaling ₹9.36 Cr. The company has closed loans amounting to ₹17.81 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Regenix Drugs Limited India are Krishanamoorthy Nirosha as CFO and Srividhya as Company Secretary. Ramamurthy Ayyavuthevar, Gunasekaran Raju, Malathi Ramamurthy, and Seven other members serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TN2007PLC063446
- Company No.
063446
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 May 2007
- Date of AGM
24 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
What products or services does Regenix Drugs Limited offer?
Regenix Drugs Limited offers a wide range of products and services, including Pathology Lab Equipments, Elisa Reader, Laboratory Equipment, Surgical & ICU Equipments, Stethoscope, Thermometers & Flowmeters, Industrial and Medical Infrared Thermometer, Analyzers & Analytical Instruments, Digital Analyzers, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Regenix Drugs?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramamurthy Ayyavuthevar  | Managing Director | 30-Jun-2007 | Current |
| Krishanamoorthy Nirosha | CFO | Current | |
| Srividhya | Company Secretary | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Guhan Ramamurthy | Director | 21-Jun-2021 | Current |
| Govindarajan Venkatakrishna | Director | 20-Mar-2010 | Current |
| Akshay Arvind | Director | 25-Sep-2022 | Current |
| Gunasekaran Raju | Director | 29-Sep-2007 | Current |
| Malathi Ramamurthy | Director | 15-Apr-2012 | Current |
| Radhakrishnan Murali | Director | Current |
Financial Performance of Regenix Drugs.
Regenix Drugs Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.38% increase. The company also saw a substantial improvement in profitability, with a 246.41% increase in profit. The company's net worth Soared by an impressive increase of 20.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regenix Drugs?
In 2023, Regenix Drugs had a promoter holding of 62.62% and a public holding of 37.38%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Regenix Biosciences LimitedRamamurthy Ayyavuthevar, Malathi Ramamurthy and 3 more are mutual person
Daa Consulting Private LimitedAkshay Arvind is a mutual person
D Arvind & Associates LlpAkshay Arvind is a mutual person
Prime Pharmaceuticals Private LimitedRamamurthy Ayyavuthevar is a mutual person
Aarthi Scans Private LimitedGovindarajan Venkatakrishna is a mutual person
Charges (Loans)
₹9.36 Cr
₹17.81 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 9.21 Cr
- Axis Bank Limited : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Sep 2023 | Hdfc Bank Limited | ₹2.12 M | Open |
| 13 Jul 2020 | Hdfc Bank Limited | ₹9.00 Cr | Open |
| 29 Jul 2015 | Axis Bank Limited | ₹1.47 M | Open |
| 17 Jul 2017 | Others | ₹7.99 Cr | Satisfied |
| 04 Feb 2013 | Others | ₹7.98 Cr | Satisfied |
How Many Employees Work at Regenix Drugs?
Regenix Drugs has a workforce of 841 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regenix Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regenix Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
